The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Side Effects of Interferon-α Therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381805 · Cited by 967
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1053/jhep.2002.36810 · Cited by 727
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
Cytokines and psychopathology: Lessons from interferon-α
Capuron, L., & Miller, A. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.009 · Cited by 562
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 422
Flier, J. S., Underhill, L. H., Saper, C. B., & Breder, C. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302609 · Cited by 374
Messing, E. M., Manola, J. B., Wilding, G., PROPERT, K. J., Fleischmann, J. D., Crawford, E. D., Pontes, J. E., Hahn, R. G., & Trump, D. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.005 · Cited by 309
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2972 · Cited by 264
Elevated plasma nitrate levels in depressive states
Suzuki, E., Yagi, G., Nakaki, T., Kanba, S., & Asai, M. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00164-6 · Cited by 255
Cancer–related fatigue: can exercise physiology assist oncologists?
Lucía, A., Earnest, C., & Pérez, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01221-x · Cited by 250
Mechanisms of fever induced by recombinant human interferon.
Dinarello, C. A., Bernheim, H. A., Duff, G. W., Le, H. V., Nagabhushan, T. L., Hamilton, N. C., & Coceani, F. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111508 · Cited by 226
The phenomenology and treatment of interferon-induced depression
Loftis, J. M., & Hauser, P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.04.002 · Cited by 226
Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy
Kirkwood, J. M., Bender, C., Agarwala, S., Tarhini, A., Shipe-Spotloe, J., Smelko, B., Donnelly, S., & Stover, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.052 · Cited by 200
Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in Mice
Dvorak, H. F., & Gresser, I. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.497 · Cited by 192
Immune-mediated side-effects of cytokines in humans
Vial, T. (1995) · Toxicology · doi:10.1016/0300-483x(95)03124-x · Cited by 181
WATANABE, U., Hashimoto, E., HISAMITSU, T., Obata, H., & Hayashi, N. (1994) · PubMed · Cited by 168
Plata‐Saláman, C. R. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801911 · Cited by 164
Effect of Interferon on Glucose Tolerance and Insulin Sensitivity
Koivisto, V. A., Pelkonen, R., & Cantell, K. (1989) · Diabetes · doi:10.2337/diab.38.5.641 · Cited by 153
Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy
Fabris, P., Floreani, A., Tositti, G., Vergani, D., de Lalla, F., & Betterle, C. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01681.x · Cited by 132
Cutaneous reactions to recombinant cytokine therapy
Asnis, L. A., & Gaspari, A. A. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)91382-3 · Cited by 119
Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.
Licinio, J., Kling, M. A., & Hauser, P. (1998) · PubMed · Cited by 118
Interferon-α Stimulates the Hypothalamic- Pituitary-Adrenal Axis in vivo and in vitro
Gisslinger, H., Svoboda, T., Clodi, M., Gilly, B., Ludwig, H., Havelec, L., & Luger, A. (2008) · Neuroendocrinology · doi:10.1159/000126396 · Cited by 111
Weijl, N. I., Harst, D. V. D., Brand, A., Kooy, Y. M. C., Luxemburg, S. V., Schroder, J., Lentjes, E. G. W. M., ROOD, J. J. V., Cleton, F. J., & Osanto, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1376 · Cited by 99
Carella, C., Mazziotti, G., Morisco, F., Manganella, G., Rotondi, M., Tuccillo, C., Sorvillo, F., Caporaso, N., & Amato, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7459 · Cited by 98
IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2
Chakrabarti, D., Hultgren, B. A., & Stewart, T. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.522 · Cited by 95
The neurologic basis of fever.
MacKenzie, M. A., Pieters, G. F., & Hermus, A. R. (1994) · PubMed · Cited by 94
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-?
Meriggioli, M. N., & Rowin, J. (2000) · Muscle & Nerve · Cited by 85
Sudden hearing loss associated with interferon
Kanda, Y., Shigeno, K., Yano, M., Kinoshita, N., Nakao, K., & Matsuo, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90237-2 · Cited by 76
Kakizaki, S., Takagi, H., Murakami, M., Takayama, H., & Mori, M. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80131-7 · Cited by 76
Vascular Events Associated with Alpha Interferon Therapy
Alzahrani, H. A., Gupta, V. K., Minden, M. D., Messner, H. A., & Lipton, J. H. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000055066 · Cited by 74
A reversal in the long-term increase in deaths attributable to malignant melanoma
Roush, G. C., McKay, L. A., & Holford, T. R. (1992) · Cancer · doi:10.1002/1097-0142(19920401)69:7<1799::aid-cncr2820690723>3.0.co;2-8 · Cited by 71
Guillot, B., Blázquez, L., Bessis, D., Dereure, O., & Guilhou, J. J. (2004) · Dermatology · doi:10.1159/000075046 · Cited by 69
Rowan, P. J., Tavakoli–Tabasi, S., Abdul-latif, M., Kunik, M. E., & El‐Serag, H. B. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000123203.36471.70 · Cited by 65
Seizures during alpha interferon therapy
Shakil, A. O., Bisceglie, A. M. D., & Hoofnagle, J. H. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80185-1 · Cited by 64
Myasthenia gravis during interferon alfa therapy
Batocchi, A. P., Evoli, A., Servidei, S., Palmisani, M. T., Apollo, F., & Tonali, P. (1995) · Neurology · doi:10.1212/wnl.45.2.382 · Cited by 64
Adams, F., Fernandez, F., & Mavligit, G. M. (1988) · Journal of Neuro-Oncology · doi:10.1007/bf00177432 · Cited by 63
Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications
Schaefer, M., Schwaiger, M., Pich, M. G. L., Lieb, K., & Heinz, A. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45131 · Cited by 61
Islam, M. F., Frye, R. F., Richards, T. J., Sbeitan, I., Donnelly, S., Glue, P., Agarwala, S. S., & Kirkwood, J. M. (2002) · PubMed · Cited by 61
Bell, T., Bansal, A. S., Shorthouse, C., Sandford, N. L., & Powell, E. E. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01896.x · Cited by 55
Neuropsychiatric side effects of interferon-alfa therapy.
Gool, A. R. V., Kruit, W. H. J., Stoter, G., Engels, F. K., & Eggermont, A. M. M. (2003) · Pharmacy World & Science · doi:10.1023/a:1022449613907 · Cited by 54
Self-citationSuppressive effect of interferon on erythroid cell proliferation.
Ortega, J. A., Ma, A. I., Shore, N. A., Dukes, P. P., & Merigan, T. C. (1979) · PubMed · Cited by 51
Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma
Merimsky, O., Reider‐Groswasser, I., Inbar, M., & Chaitchik, S. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90086-9 · Cited by 46
Ito, Y., Takeda, N., Ishimori, M., Akai, A., Miura, K., & Yasuda, K. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80216-5 · Cited by 34
Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α
Fernández‐Miranda, C., Castellano, G., Guijarro, C., Fernández, I., Schöebel, N., Larumbe, S., Gómez‐Izquierdo, T., & del Palacio, A. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00427-4 · Cited by 34
Nephrotoxicity of Interferon Alfa–Ribavirin Therapy for Chronic Hepatitis C
Willson, R. A. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200207000-00019 · Cited by 33
Reversible hypopituitarism after interferonalfa therapy
Sakane, N., Yoshida, T., Yoshioka, K., Umekawa, T., Kondo, M., & Shimatsu, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90950-8 · Cited by 33
Interferon-induced hypopituitarism
Concha, L. B., Carlson, H. E., Heimann, A., Lake‐Bakaar, G., & Paal, A. F. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01323-2 · Cited by 32
Multiple sclerosis-like disease secondary to alpha interferon
Matsuo, T., & Takabatake, R. (2002) · Ocular Immunology and Inflammation · doi:10.1076/ocii.10.4.299.15588 · Cited by 32
Acute effects of interferon-alpha administration on testosterone concentrations in healthy men
Corssmit, E. P. M., Endert, E., Sauerwein, H. P., & Romijn, J. A. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430371 · Cited by 21
Uncommon side‐effects of interferon
Bailly, F., Mattei, A., Si‐Ahmed, S. N., & TREPO, C. G. (1997) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.1997.tb00167.x · Cited by 17
Acute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C
Gabrielli, M., Santarelli, L., Serricchio, M., Leo, D. D., Pola, P., & Gasbarrini, A. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07367.x · Cited by 13
Hendrix, C. W., Petty, B. G., Woods, A. S., Kuwahara, S. K., Witter, F. R., Soo, W., Griffin, D. E., & Lietman, P. S. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00043-l · Cited by 4
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Commensal Microbiota Modulation of Natural Resistance to Virus Infection
Stefan, K. L., Kim, M. V., Iwasaki, A., & Kasper, D. L. (2020) · Cell · doi:10.1016/j.cell.2020.10.047 · Cited by 295
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
“However, the clinical utilization of type I IFNs has been limited because of severe peripheral toxicity when it is delivered systemically (68).”
Background
Metadata
- Authors
- Sleijfer, S., Bannink, M., Gool, A. R., Kruit, W. H. J., & Stoter, G.
- Venue
- Pharmacy World & Science
- Published
- 2005-12
- Volume
- 27
- Issue
- 6
- Pages
- 423-431
- ISSN
- 0167-6555 (ISSN-L)
- 0928-1231
- 1573-739X
- OpenAlex
- W2048227276
- Cited by
- 276
- References
- 57
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.